Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).

Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H

Diabetes, obesity & metabolism28 Feb 2023Cited by 21 (Europe PMC)

PMID36722623DOI10.1111/dom.14998PepBankPUB-36722623

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from dulaglutide to semaglutide lowered HbA1c more than continuing dulaglutide (7.1% vs 7.9% at 24 weeks, p < .01).
In plain wordsIn adults with type 2 diabetes, switching from dulaglutide to semaglutide lowered HbA1c more than staying on dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change over 24 weeks, switch from dulaglutide (plan B)
Study
n = 63
Comparator
Continued dulaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c at 24 weeks
7.1%
semaglutide, plan B
HbA1c at 24 weeks
7.9%
dulaglutide, plan B
Source sentences
Summary
plan B, 7.8% ± 1.0% to 7.9% ± 1.2% (dulaglutide) vs. 7.8% ± 0.8% to 7.1% ± 0.6% (semaglutide), p < .01
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262302
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes who continued dulaglutide, HbA1c was higher at 24 weeks than in those who switched to semaglutide (7.9% vs 7.1%).
In plain wordsIn patients with diabetes, HbA1c, a measure of average blood sugar, was higher with continued dulaglutide than after switching to semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGlycated haemoglobin
Study
n = 63
Comparator
Switch to semaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Measurements
Glycated haemoglobin
7.8%
Continued dulaglutide, baseline
Glycated haemoglobin
7.9%
Continued dulaglutide, 24 weeks
Glycated haemoglobin
7.8%
Switch to semaglutide, baseline
Glycated haemoglobin
7.1%
Switch to semaglutide, 24 weeks
Source sentences
Summary
plan B, 7.8% ± 1.0% to 7.9% ± 1.2% (dulaglutide) vs. 7.8% ± 0.8% to 7.1% ± 0.6% (semaglutide), p < .01].
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262307
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from liraglutide to semaglutide lowered HbA1c more than continuing liraglutide (7.3% vs 7.8% at 24 weeks, p < .01).
In plain wordsIn adults with type 2 diabetes, switching from liraglutide to semaglutide lowered HbA1c more than staying on liraglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change over 24 weeks, switch from liraglutide (plan A)
Study
n = 37
Comparator
Continued liraglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c at 24 weeks
7.3%
semaglutide, plan A
HbA1c at 24 weeks
7.8%
liraglutide, plan A
Source sentences
Summary
plan A, 7.8% ± 1.0% to 7.8% ± 0.7% (liraglutide) vs. 7.9% ± 0.7% to 7.3% ± 0.7% (semaglutide), p < .01
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262301
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from dulaglutide to semaglutide improved Diabetes Treatment Satisfaction Questionnaire scores more than continuing dulaglutide (+3.5 vs -1.2, p < .01).
In plain wordsIn adults with type 2 diabetes, switching from dulaglutide to semaglutide raised treatment satisfaction more than staying on dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseTreatment satisfaction (DTSQ score), switch from dulaglutide (plan B)
Study
n = 63
Comparator
Continued dulaglutide
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
DTSQ score change
3.5
semaglutide, plan B
DTSQ score change
−1.2
dulaglutide, plan B
Source sentences
Summary
plan B, -1.2 vs. +3.5, p < .01
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262304
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from dulaglutide to semaglutide gave greater reductions in body weight.
In plain wordsIn adults with type 2 diabetes, switching from dulaglutide to semaglutide gave greater weight loss.
Peptide
Semaglutide
Outcome
DecreaseBody weight, switch from dulaglutide
Study
n = 63
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262305
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from dulaglutide to semaglutide improved metabolic parameters.
In plain wordsIn adults with type 2 diabetes, switching from dulaglutide to semaglutide improved metabolic measures.
Peptide
Semaglutide
Outcome
Direction not reportedMetabolic indices, switch from dulaglutide
Study
n = 63
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262306
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, treatment satisfaction scores decreased with continued dulaglutide but increased after switching to semaglutide.
In plain wordsIn patients with diabetes, treatment satisfaction scores decreased with continued dulaglutide but increased after switching to semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTreatment satisfaction score
Study
n = 63
Comparator
Switch to semaglutide
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Measurements
Treatment satisfaction score change
−1.2 points
Continued dulaglutide, change in DTSQ score
Treatment satisfaction score change
3.5 points
Switch to semaglutide, change in DTSQ score
Source sentences
Summary
Semaglutide also improved Diabetes Treatment Satisfaction Questionnaire scores in both groups (plan A, +0.1 vs. +8.3, p < .01; plan B, -1.2 vs. +3.5, p < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262308
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, switching from dulaglutide to semaglutide produced greater weight reductions than continuing dulaglutide.
In plain wordsIn patients with diabetes, switching from dulaglutide to semaglutide produced greater weight reductions than continuing dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBody weight
Study
n = 63
Comparator
Switch to semaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262309
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from liraglutide to semaglutide improved Diabetes Treatment Satisfaction Questionnaire scores more than continuing liraglutide (+8.3 vs +0.1, p < .01).
In plain wordsIn adults with type 2 diabetes, switching from liraglutide to semaglutide raised treatment satisfaction more than staying on liraglutide.
Peptide
Semaglutide
Outcome
IncreaseTreatment satisfaction (DTSQ score), switch from liraglutide (plan A)
Study
n = 37
Comparator
Continued liraglutide
Analysis
Secondary
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
DTSQ score change
8.3
semaglutide, plan A
DTSQ score change
0.1
liraglutide, plan A
Source sentences
Summary
Semaglutide also improved Diabetes Treatment Satisfaction Questionnaire scores in both groups (plan A, +0.1 vs. +8.3, p < .01
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy.
Report a problemFND-3672262303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06243536

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

University Hospital Sestre Milosrdnicen = 60est. 1 Feb 2024 to est. 31 Dec 2024

Type 2 Diabetes · Overweight · Disordered Eating Behaviors

Trial page ClinicalTrials.govUpdated 6 Feb 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 5 to 10Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 4
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC